C-ENDO Diabetes and Endocrinology Clinic, Calgary, Alberta, Canada.
Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Diabetes Obes Metab. 2023 Sep;25(9):2553-2560. doi: 10.1111/dom.15140. Epub 2023 May 29.
To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg).
HbA1c and body weight data at 40 weeks (SURPASS-1, -2 and -5) and 52 weeks (SURPASS-3 and -4) were analysed by trial.
Across the SURPASS clinical trials, HbA1c reductions from baseline were observed in 96%-99%, 98%-99% and 94%-99% of participants treated with tirzepatide 5, 10 and 15 mg, respectively. Moreover, 87%-94%, 88%-95% and 88%-97% of participants, respectively, experienced weight loss associated with HbA1c reductions. Statistically significant associations (correlation coefficients ranging from 0.1438 to 0.3130 across studies; P ≤ .038) between HbA1c and body weight changes were observed with tirzepatide in SURPASS-2, -3, -4 (all doses) and -5 (tirzepatide 5 mg only).
In this post hoc analysis, consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg. A statistically significant but modest association between HbA1c and body weight change was observed in SURPASS-2, SURPASS-3 and SURPASS-4, suggesting that both weight-independent and weight-dependent mechanisms are responsible for the tirzepatide-induced improvement in glycaemic control.
评估替西帕肽治疗（5、10 或 15mg）与 HbA1c 和体重减轻的关系。
通过试验分析了 40 周（SURPASS-1、-2 和-5）和 52 周（SURPASS-3 和-4）时的 HbA1c 和体重数据。
在 SURPASS 临床试验中，分别接受替西帕肽 5、10 和 15mg 治疗的参与者中，有 96%-99%、98%-99%和 94%-99%观察到从基线的 HbA1c 降低。此外，分别有 87%-94%、88%-95%和 88%-97%的参与者经历了与 HbA1c 降低相关的体重减轻。在 SURPASS-2、-3、-4（所有剂量）和-5（仅替西帕肽 5mg）中，替西帕肽与 HbA1c 和体重变化之间观察到了统计学上显著的关联（相关性系数在研究中从 0.1438 到 0.3130 不等；P≤0.038）。
在这项事后分析中，大多数接受替西帕肽 5、10 或 15mg 剂量治疗的参与者均观察到 HbA1c 和体重的一致降低。在 SURPASS-2、SURPASS-3 和 SURPASS-4 中观察到 HbA1c 和体重变化之间存在统计学显著但适度的关联，表明体重独立和体重依赖机制均对替西帕肽改善血糖控制有作用。
